NSE ScannerPharmaceuticals · Pharmaceuticals: Other · NSE: LYKALABS · data 2026-10-30
Lyka Labs Limited
In plain words
Price: 20.2% below its 52-week high of ₹96.
Delivery: 61.2% of traded shares were kept for delivery over the last 10 sessions, against 62.6% over the last 60.
Latest results: a net profit of ₹1 cr for the quarter ended Sept 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹138 cr |
| Net profit (last 12 months) | ₹-9 cr |
| Sales growth, 3 years (yearly) | 11.8% |
| Profit growth, 3 years (yearly) | — |
Latest results in brief (Q2 FY27)
LYKALABS Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹44.2 crore, up 20.6% YoY and up 4.5% QoQ.
Net profit was ₹1.29 crore, a turn to profit from a loss a year ago and down 37.7% QoQ.
Operating margin was 8% (6.9% a year ago).
EPS was ₹0.36, positive against a negative EPS a year ago and down 36.8% QoQ.
LYKALABS के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹44.2 करोड़; पिछले साल की तुलना में 20.6% की बढ़त, पिछली तिमाही की तुलना में 4.5% की बढ़त।
शुद्ध मुनाफ़ा: ₹1.29 करोड़; एक साल पहले के घाटे से मुनाफ़े में आया, पिछली तिमाही की तुलना में 37.7% की गिरावट।
ऑपरेटिंग मार्जिन: 8% (एक साल पहले 6.9%)।
EPS: ₹0.36; एक साल पहले के ऋणात्मक EPS से धनात्मक हुआ, पिछली तिमाही की तुलना में 36.8% की गिरावट।
LYKALABSના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹44.2 કરોડ; ગયા વર્ષની સરખામણીએ 20.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 4.5% વધારો.
ચોખ્ખો નફો: ₹1.29 કરોડ; એક વર્ષ પહેલાંની ખોટમાંથી નફામાં આવી, ગયા ક્વાર્ટરની સરખામણીએ 37.7% ઘટાડો.
ઓપરેટિંગ માર્જિન: 8% (એક વર્ષ પહેલાં 6.9%).
EPS: ₹0.36; એક વર્ષ પહેલાંના નકારાત્મક EPSથી હકારાત્મક થઈ, ગયા ક્વાર્ટરની સરખામણીએ 36.8% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 30 Oct 26Results Q2 FY27 results: turned to profit vs a year ago
- 10 Aug 26Results Q1 FY27 results: profit +107.0% YoY +1.9% next session
- 25 May 26Results Q4 FY26 results: turned to loss vs a year ago -2.6% next session
- 29 Jan 26Results Q3 FY26 results: turned to loss vs a year ago -4.4% next session
- 13 Nov 25Results Q2 FY26 results: turned to loss vs a year ago -4.7% next session
- 1 Aug 25Results Q1 FY26 results: profit −30.6% YoY -6.7% next session
- 26 May 25Results Q4 FY25 results: turned to profit vs a year ago -1.7% next session
- 4 Feb 25Results Q3 FY25 results: profit +51.1% YoY -0.1% next session
- 12 Nov 24Results Q2 FY25 results: turned to profit vs a year ago -4.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹44 cr | ₹1 cr | — | 8.0% | 0.36 |
| Jun 2026 | ₹42 cr | ₹2 cr | +107.0% | 10.7% | 0.57 |
| Mar 2026 | ₹28 cr | ₹-8 cr | -529.9% | -23.0% | -2.13 |
| Dec 2025 | ₹31 cr | ₹-0 cr | -105.6% | 5.4% | 0 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 58.45% | 58.45% | 58.16% | 58.16% |
| Foreign institutions (FII) | 0.15% | 0.17% | 0.29% | 0.17% |
| Domestic institutions (DII) | 0.66% | 0.66% | 0.67% | 0.67% |
| Mutual funds | 0.01% | 0.01% | 0.01% | 0.01% |
| Retail investors | 21.15% | 21.20% | 21.10% | 21.62% |
| Number of shareholders | 25,885 | 29,369 | 26,727 | 27,155 |
Common questions
What was Lyka Labs Limited's latest quarterly profit?
Lyka Labs Limited reported a net profit of ₹1 cr for the quarter ended Sept 2026, on revenue of ₹44 cr.
How much do promoters hold in Lyka Labs Limited?
Promoters held 58.45% of Lyka Labs Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Lyka Labs Limited debt-free?
Its latest reported debt-to-equity ratio is 0.53.
What is the 52-week high and low of Lyka Labs Limited?
The 52-week high is ₹96 and the 52-week low is ₹44.1.
Similar companies
Amrutanjan Health Care Limited (AMRUTANJAN) · Shri Ahimsa Naturals Limited (SHRIAHIMSA) · Influx Healthtech Limited (INFLUX) · Sat Kartar Life Limited (SATKARTAR) · Natural Capsules Limited (NATCAPSUQ)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open LYKALABS in NSE Scanner →